182 related articles for article (PubMed ID: 30637228)
1. Sulfonylurea and neuroprotection: The bright side of the moon.
Hussien NR; Al-Naimi MS; Rasheed HA; Al-Kuraishy HM; Al-Gareeb AI
J Adv Pharm Technol Res; 2018; 9(4):120-123. PubMed ID: 30637228
[TBL] [Abstract][Full Text] [Related]
2. Profile of intravenous glyburide for the prevention of cerebral edema following large hemispheric infarction: evidence to date.
King ZA; Sheth KN; Kimberly WT; Simard JM
Drug Des Devel Ther; 2018; 12():2539-2552. PubMed ID: 30147301
[TBL] [Abstract][Full Text] [Related]
3. Resveratrol binds to the sulfonylurea receptor (SUR) and induces apoptosis in a SUR subtype-specific manner.
Hambrock A; de Oliveira Franz CB; Hiller S; Grenz A; Ackermann S; Schulze DU; Drews G; Osswald H
J Biol Chem; 2007 Feb; 282(5):3347-56. PubMed ID: 17138562
[TBL] [Abstract][Full Text] [Related]
4. Sulfonylurea receptor 1 contributes to the astrocyte swelling and brain edema in acute liver failure.
Jayakumar AR; Valdes V; Tong XY; Shamaladevi N; Gonzalez W; Norenberg MD
Transl Stroke Res; 2014 Feb; 5(1):28-37. PubMed ID: 24443056
[TBL] [Abstract][Full Text] [Related]
5. Glibenclamide in cerebral ischemia and stroke.
Simard JM; Sheth KN; Kimberly WT; Stern BJ; del Zoppo GJ; Jacobson S; Gerzanich V
Neurocrit Care; 2014 Apr; 20(2):319-33. PubMed ID: 24132564
[TBL] [Abstract][Full Text] [Related]
6. Glimepiride and glibenclamide have comparable efficacy in treating acute ischemic stroke in mice.
Wang X; Chang Y; He Y; Lyu C; Li H; Zhu J; Liu K; Hu Y; Huang K; Pan S
Neuropharmacology; 2020 Jan; 162():107845. PubMed ID: 31704276
[TBL] [Abstract][Full Text] [Related]
7. SUR1-TRPM4 channels, not K
Woo SK; Tsymbalyuk N; Tsymbalyuk O; Ivanova S; Gerzanich V; Simard JM
Neurosci Lett; 2020 Jan; 718():134729. PubMed ID: 31899311
[TBL] [Abstract][Full Text] [Related]
8. Glibenclamide for the treatment of ischemic and hemorrhagic stroke.
Caffes N; Kurland DB; Gerzanich V; Simard JM
Int J Mol Sci; 2015 Mar; 16(3):4973-84. PubMed ID: 25749474
[TBL] [Abstract][Full Text] [Related]
9. Glibenclamide Produces Region-Dependent Effects on Cerebral Edema in a Combined Injury Model of Traumatic Brain Injury and Hemorrhagic Shock in Mice.
Jha RM; Molyneaux BJ; Jackson TC; Wallisch JS; Park SY; Poloyac S; Vagni VA; Janesko-Feldman KL; Hoshitsuki K; Minnigh MB; Kochanek PM
J Neurotrauma; 2018 Sep; 35(17):2125-2135. PubMed ID: 29648981
[TBL] [Abstract][Full Text] [Related]
10. Influence of glibenclamide on outcome in patients with type 2 diabetes and traumatic brain injury.
Ding J; Yuan F; Guo JY; Chen H; Tian HL
Clin Neurol Neurosurg; 2013 Oct; 115(10):2166-9. PubMed ID: 23998719
[TBL] [Abstract][Full Text] [Related]
11. The short form of the SUR1 and its functional implications in the damaged brain.
Alquisiras-Burgos I; Franco-Pérez J; Rubio-Osornio M; Aguilera P
Neural Regen Res; 2022 Mar; 17(3):488-496. PubMed ID: 34380876
[TBL] [Abstract][Full Text] [Related]
12. Combination Therapy with a Dipeptidyl Peptidase-4 Inhibitor, Sulfonylurea, and Metformin Markedly Improves HbA1c Levels in Japanese Patients with Type 2 Diabetes Mellitus.
Hirao K; Maeda H; Shirabe S; Yamamoto R; Hirao T; Hirao S; Yamauchi M; Arai K
Jpn Clin Med; 2012; 3():1-7. PubMed ID: 23946679
[TBL] [Abstract][Full Text] [Related]
13. Glibenclamide, a Sur1-Trpm4 antagonist, does not improve outcome after collagenase-induced intracerebral hemorrhage.
Wilkinson CM; Brar PS; Balay CJ; Colbourne F
PLoS One; 2019; 14(5):e0215952. PubMed ID: 31042750
[TBL] [Abstract][Full Text] [Related]
14. The beneficial effect of α-glucosidase inhibitor on glucose variability compared with sulfonylurea in Taiwanese type 2 diabetic patients inadequately controlled with metformin: preliminary data.
Lin SD; Wang JS; Hsu SR; Sheu WH; Tu ST; Lee IT; Su SL; Lin SY; Wang SY; Hsieh MC
J Diabetes Complications; 2011; 25(5):332-8. PubMed ID: 21813293
[TBL] [Abstract][Full Text] [Related]
15. Role of Sulfonylurea Receptor 1 and Glibenclamide in Traumatic Brain Injury: A Review of the Evidence.
Jha RM; Bell J; Citerio G; Hemphill JC; Kimberly WT; Narayan RK; Sahuquillo J; Sheth KN; Simard JM
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936452
[TBL] [Abstract][Full Text] [Related]
16. Combination treatment with metformin and glibenclamide versus single-drug therapies in type 2 diabetes mellitus: a randomized, double-blind, comparative study.
Tosi F; Muggeo M; Brun E; Spiazzi G; Perobelli L; Zanolin E; Gori M; Coppini A; Moghetti P
Metabolism; 2003 Jul; 52(7):862-7. PubMed ID: 12870162
[TBL] [Abstract][Full Text] [Related]
17. Sulfonylurea receptors inhibit the epithelial sodium channel (ENaC) by reducing surface expression.
Konstas AA; Bielfeld-Ackermann A; Korbmacher C
Pflugers Arch; 2001 Aug; 442(5):752-61. PubMed ID: 11512032
[TBL] [Abstract][Full Text] [Related]
18. [Glibenclamide as a promising agent for prevention and treatment of cerebral edema].
Tsarenko SV; Dzyadz'ko AM; Rybalko SS
Zh Vopr Neirokhir Im N N Burdenko; 2017; 81(3):88-93. PubMed ID: 28665392
[TBL] [Abstract][Full Text] [Related]
19. How long can insulin therapy be avoided in the patient with type 2 diabetes mellitus by use of a combination of metformin and a sulfonylurea?
Bell DS; Ovalle F
Endocr Pract; 2000; 6(4):293-5. PubMed ID: 11242605
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy with insulin glargine plus metformin but not insulin glargine plus sulfonylurea provides similar glycemic control to triple oral combination therapy in patients with type 2 diabetes uncontrolled with dual oral agent therapy.
Hollander P; Sugimoto D; Vlajnic A; Kilo C
J Diabetes Complications; 2015; 29(8):1266-71. PubMed ID: 26281972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
